latest news releases from the newsroom
Overseas Shipholding Group, Inc.
Third Quarter 2005 Earnings Results
NEW YORK, Nov. 3, 2005 (PRIMEZONE) -- Overseas Shipholding Group, Inc. (NYSE:OSG) today announced results for the third quarter and year-to-date fiscal year 2005. Net income for the quarter ended September 30, 2005 of $72.1 million, or $1.82 per diluted share, increased 5.2% compared with net income of $68.5 million, or $1.74 per diluted share, in the third quarter of 2004. TCE revenues for the quarter were $194.8 million compared with $167.9 million, an increase of 16.0% year-over-year. EBITDA for the third quarter 2005 declined 6.9% to $135.4 million from $145.4 million in the third quarter of 2004. The decrease in EBITDA was principally attributable to a decline in TCE rates for VLCCs and Aframaxes in the third quarter of 2005 compared with the year ago period. See Appendix 3 for a reconciliation of EBITDA.
Yard Sale Drop-Off Distributors Launch Aggressive Marketing Plans
Ft. LAUDERDALE, Fla., November 3, 2005 (PRIMEZONE) -- Total Identity Corp. ("TIC") (Pink Sheets:TIDC) today announced that the distributors for its wholly-owned subsidiary, Yard Sale Drop Off ("YSDO"), a trading assistant and Power Seller with eBay (NASDAQ "EBAY"), have launched aggressive marketing efforts in both the United States and Canada to market the Commerce Management Suite ("CMS").
Urban Outfitters, Inc.
Urban Outfitters Q3 Sales Jump 33 Percent
PHILADELPHIA, Nov. 3, 2005 (PRIMEZONE) -- Urban Outfitters, Inc. (Nasdaq:URBN), a leading lifestyle consumer products company operating under the Urban Outfitters, Anthropologie and Free People brands, today announced sales for the three and nine months ended October 31, 2005.
Aquila's Utility Operations Continue Their Solid Performance; Debt Reduction Costs Reduce Third Quarter Earnings
KANSAS CITY, Mo., Nov. 3, 2005 (PRIMEZONE) -- Aquila, Inc. (NYSE:ILA) today reported stronger third quarter performance in its electric and natural gas utility businesses; however, the company's earnings were adversely affected by the costs of remaining obligations related to the former merchant business and the costs of reducing debt. A loss of $.20 per fully diluted share was reported for the three months ended September 30, 2005, or a net loss of $75.7 million, compared to a loss of $.44 per fully diluted share, or a net loss of $116.4 million, for the third quarter of 2004. Sales from continuing operations were $319.8 million in this year's third quarter, up from $218.8 million in the same quarter last year.
Standard Chartered -- Analyst Trip
LONDON, Nov. 3, 2005 (PRIMEZONE) -- SC First Bank investor documentary. Investor documentary available now on www.cantos.com highlighting the operations and strengths of SC First Bank and the opportunities for the bank in Korea and internationally. The film features interviews with Standard Chartered (LSE:STAN) Group CEO, Mervyn Davies and key members of SC First Bank management.
Effnet: Factum Enables DAB/DMB Transmission in the Czech Republic
STOCKHOLM, Sweden, Nov. 3, 2005 (PRIMEZONE) -- Effnet: in conjunction with the WorldDAB General Assembly in the Czech Republic, Factum Electronics has provided a head end system for DAB/DMB transmissions in cooperation with the network operator TELEKO, system integrator Antonin Couf - E.M.U. Servis and the public broadcaster Czech Radio. During the event it will be possible to experience a number of DAB/DMB services in Prague.
Active Biotech to Present at the SG Cowen & Company 6th Annual
STOCKHOLM, Sweden, Nov. 3, 2005 (PRIMEZONE) -- Active Biotech (Stockholm: ACTI.ST) management will present at the SG Cowen & Company 6th Annual Global Health Care Conference at 16.20 (CET) / 10:40 a.m. (ET) on Thursday, November 10 at The Hilton Diagonal Mar, in Barcelona, Spain. During the presentation, management will provide an update on the Active Biotech development program, as well as offer insight into its financial results.The presentation will include an update on the following drugs: laquinimod, the company's oral MS drug for which it is in partnership with Teva Pharmaceutical Industries Ltd.; ANYARA, Active Biotech's novel concept for the treatment of lung cancer; and other key projects in clinical development, such as TASQ, for prostate cancer; 57-57, for Lupus (SLE); and RhuDex(R) (licensed to Avidex Ltd.) for rheumatoid arthritis.